Production (Stage)
Foghorn Therapeutics Inc.
FHTX
$4.54
-$0.04-0.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.95M | 2.86M | 7.81M | 6.89M | 5.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.95M | 2.86M | 7.81M | 6.89M | 5.05M |
| Cost of Revenue | 21.63M | 20.51M | 24.69M | -- | 25.53M |
| Gross Profit | -15.67M | -17.65M | -16.88M | 6.89M | -20.48M |
| SG&A Expenses | 7.24M | 6.35M | 6.97M | 7.33M | 7.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.87M | 26.86M | 31.66M | 31.12M | 33.24M |
| Operating Income | -22.91M | -24.01M | -23.85M | -24.23M | -28.19M |
| Income Before Tax | -18.83M | -19.50M | -19.12M | -22.98M | -25.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.83M | -19.50M | -19.12M | -22.98M | -25.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.83M | -19.50M | -19.12M | -22.98M | -25.02M |
| EBIT | -22.91M | -24.01M | -23.85M | -24.23M | -28.19M |
| EBITDA | -22.09M | -23.24M | -23.12M | -23.44M | -27.36M |
| EPS Basic | -0.30 | -0.31 | -0.31 | -0.45 | -0.59 |
| Normalized Basic EPS | -0.19 | -0.19 | -0.19 | -0.25 | -0.37 |
| EPS Diluted | -0.30 | -0.31 | -0.31 | -0.45 | -0.59 |
| Normalized Diluted EPS | -0.19 | -0.19 | -0.19 | -0.25 | -0.37 |
| Average Basic Shares Outstanding | 62.85M | 62.87M | 62.60M | 51.58M | 42.43M |
| Average Diluted Shares Outstanding | 62.85M | 62.87M | 62.60M | 51.58M | 42.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |